Skip to main content
. 2023 Oct 24;15:1254824. doi: 10.3389/fnagi.2023.1254824

Table 3.

The influence of relevant factors on Hcy in PD patients in the meta-analysis.

Factors Sample size No. of studies SMD [95% CI] P value Test of heterogeneity Egger’s test for publication bias
case control I 2 P value t p value
Hhcy 38 (Yes) 69 (No) 3 10.82 [8.92, 12.71] <0.001 0 0.90 1.57 0.1172
H and Y 96 (4 ~ 5) 156 (2 ~ 3) 1 0.45 [0.19,0.70] <0.001 / / / /
96 (4 ~ 5) 61 (1 ~ 2) 1 0.46 [0.15,0.78] <0.001 / / / /
315 (2 ~ 3) 61 (1 ~ 2) 4 0.34 [−0.04,0.72] 0.08 71 0.02 1.36 0.1742
Levodopa therapy 162 (Yes) 58 (No) 3 0.72 [0.08, 1.36] 0.03 71 0.03 0.52 0.6015
CI or dementia 221 (Yes) 438 (No) 5 0.54 [0.38, 0.71] <0.001 7 0.37 −0.98 0.3272
Age 103 (70~) 129 (60 ~ 70) 3 0.58 [0.30, 0.85] <0.001 0 0.82 0.52 0.6015
24 (70~) 30 (~60) 2 0.84 [0.28, 1.41] 0.004 35 0.22 / /
45 (60 ~ 70) 14 (~60) 1 0.78 [0.16, 1.39] 0.01 / / / /

H and Y, Hoehn and Yahr Stage; CI, cognitive impairment.